

PATENT APPLICATION
Attorney Docket No. 28111/32729B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:)	For: Methods for Producing
)	Members of Specific Binding
McCafferty <i>et al.</i>)	Pairs
)	
Serial No.: 09/417,478)	Group Art Unit: 1627
)	
Filed: October 13, 1999)	Examiner: P. Ponnaluri

#7

TERMINAL DISCLAIMER

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Cambridge Antibody Technology Limited (CAT), a British company, The Science Park, Melbourne, Royston, Cambridgeshire SG8 6JJ ENGLAND and Medical Research Council (MRC), a British company, 20 Park Crescent, London WIN 4AL ENGLAND are the owners of the entire right, title, and interest in the above-identified patent application U.S. Serial No. 09/417,478.

Assignees hereby disclaim the terminal portion of the term of any patent granted on U.S. serial number 09/417,478 extending beyond the expiration date of U.S. Patent No. 5,969,108 and hereby agree that any patent so granted on U.S. Serial No. 09/417,478 shall be enforceable only for and during such period that

09/12/2000 TSUGGS 0000001-12835 09/417,478 the legal title to said patent and the legal title to any patent granted on U.S. serial number 09/417,478 are commonly owned, this agreement to run with any patent granted on U.S. serial number 09/417,478 and to be binding upon assignees and its successors or assigns.

01 FC:148

110.00

Assignees do not disclaim any terminal portion of the term of any patent granted on U.S. serial number 09/417,478 prior to the expiration date of the full statutory term of U.S. Patent No. 5,969,108 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or in part or is terminally disclaimed under 37 CFR

§1.321 (a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title stated above.


The documents establishing the assignees' chain of title have been reviewed by the undersigned and the undersigned certifies that to the best of his/her knowledge and belief, title is in the assignees.

The undersigned is empowered to act on behalf of the assignees, Cambridge Antibody Technology Limited and Medical Research Council.

The Commissioner is hereby authorized to charge the requisite fee of \$110.00 for submission of a terminal disclaimer to Deposit Account No. 13-2855.

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN

By



David W. Clough
Registration No. 36,107

February 24, 2000